1. Home
  2. VRCA

as 04-17-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Founded: 2013 Country:
United States
United States
Employees: N/A City: WEST CHESTER
Market Cap: 58.0M IPO Year: 2018
Target Price: $6.00 AVG Volume (30 days): 607.0K
Analyst Decision: Hold Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.48 EPS Growth: N/A
52 Week Low/High: $0.38 - $11.41 Next Earning Date: 05-12-2025
Revenue: $7,566,000 Revenue Growth: 47.66%
Revenue Growth (this year): 127.58% Revenue Growth (next year): 88.06%

VRCA Daily Stock ML Predictions

Stock Insider Trading Activity of Verrica Pharmaceuticals Inc. (VRCA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Hayes Christopher G. VRCA CHIEF LEGAL OFFICER Mar 14 '25 Sell $0.65 4,315 $2,804.75 176,458

Share on Social Networks: